BIOGRAPHY
Dr. David J Leggat is an academia and biotechnology experienced researcher in the field of Influenza vaccination and detection. Dr. Leggat received his Ph.D. from the University of Toledo Health Science Campus within the department of Medicine and the Infection, Immunity & Transplantation track studying pneumococcal vaccination in HIV and elderly patients. Expanding on his experience in flow cytometry, he joined the Vaccine Research Center at the National Institutes of Health as a post-doc. He transitioned as a contract scientist within the Vaccine Immunology Program, leading vaccine-specific B cell analysis post-HIV vaccination for Bill & Melinda Gates Foundation funded studies with IAVI as part of the CAVD as well as VRC lead pre-clinical and clinical HIV vaccine studies.
Dr. Leggat joined MHRP as a government civilian in 2022 leading the Cellular Immune Monitoring and Flow Cytometry cores and focusing on the study of antigen-specific vaccination responses in pre-clinical and clinical trials.
Selected Publications
Leggat DJ, Cohen KW, Willis JR, Fulp WJ, deCamp AC, Kalyuzhniy O, Cottrell CA, Menis S, Finak G, Ballweber-Fleming L, Srikanth A, Plyler JR, Schiffner T, Liguori A, Rahaman F, Lombardo A, Philiponis V, Whaley RE, Seese A, Brand J, Ruppel AM, Hoyland W, Yates NL, Williams LD, Greene K, Gao H, Mahoney CR, Corcoran MM, Cagigi A, Taylor A, Brown DM, Ambrozak DR, Sincomb T, Hu X, Tingle R, Georgeson E, Eskandarzadeh S, Alavi N, Lu D, Mullen TM, Kubitz M, Groschel B, Maenza J, Kolokythas O, Khati N, Bethony J, Crotty S, Roederer M, Karlsson Hedestam GB, Tomaras GD, Montefiori D, Diemert D, Koup RA, Laufer DS, McElrath MJ, McDermott AB, Schief WR. Vaccination induces HIV broadly neutralizing antibody precursors in humans. Science. 2022 Dec 2;378(6623):eadd6502. doi: 10.1126/science.add6502. Epub 2022 Dec 2. PMID: 36454825.
Townsley SM, Leggat DJ, Prabhakaran M, McDermott AB, Krebs SJ. Sequential staining of HIV gp140 to capture antigen-specific human B cells via flow cytometry. STAR Protoc. 2021 Aug 24;2(3):100771. doi: 10.1016/j.xpro.2021.100771. PMID: 34471908.
Townsley SM, Donofrio GC, Jian N, Leggat DJ, Dussupt V, Mendez-Rivera L, Eller LA, Cofer L, Choe M, Ehrenberg PK, Geretz A, Gift S, Grande R, Lee A, Peterson C, Piechowiak MB, Slike BM, Tran U, Joyce MG, Georgiev IS, Rolland M, Thomas R, Tovanabutra S, Doria-Rose NA, Polonis VR, Mascola JR, McDermott AB, Michael NL, Robb ML, Krebs SJ. B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies. Cell Host Microbe. 2021 Apr 14;29(4):564-578.e9. doi: 10.1016/j.chom.2021.01.016. Epub 2021 Mar 3. PMID: 33662277.
Eslamizar L, Petrovas C, Leggat DJ, Furr K, Lifton ML, Levine G, Ma S, Fletez-Brant C, Hoyland W, Prabhakaran M, Narpala S, Boswell K, Yamamoto T, Liao HX, Pickup D, Ramsburg E, Sutherland L, McDermott A, Roederer M, Montefiori D, Koup RA, Haynes BF, Letvin NL, Santra S. Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center. NPJ Vaccines. 2021 Jan 25;6(1):15. doi: 10.1038/s41541-020-00277-1. PMID: 33495459.
Dussupt V, Sankhala RS, Gromowski GD, Donofrio G, De La Barrera RA, Larocca RA, Zaky W, Mendez-Rivera L, Choe M, Davidson E, McCracken MK, Brien JD, Abbink P, Bai H, Bryan AL, Bias CH, Berry IM, Botero N, Cook T, Doria-Rose NA, Escuer AGI, Frimpong JA, Geretz A, Hernandez M, Hollidge BS, Jian N, Kabra K, Leggat DJ, Liu J, Pinto AK, Rutvisuttinunt W, Setliff I, Tran U, Townsley S, Doranz BJ, Rolland M, McDermott AB, Georgiev IS, Thomas R, Robb ML, Eckels KH, Barranco E, Koren M, Smith DR, Jarman RG, George SL, Stephenson KE, Barouch DH, Modjarrad K, Michael NL, Joyce MG, Krebs SJ. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. Nat Med. 2020 Feb;26(2):228-235. doi: 10.1038/s41591-019-0746-2. Epub 2020 Feb 3. PMID: 32015557.
Angeletti D, Gibbs JS, Angel M, Kosik I, Hickman HD, Frank GM, Das SR, Wheatley AK, Prabhakaran M, Leggat DJ, McDermott AB, Yewdell JW. Defining B cell immunodominance to viruses. Nat Immunol. 2017 Apr;18(4):456-463. doi: 10.1038/ni.3680. Epub 2017 Feb 13. PMID: 28192417.
Ohtola JA, Saul-McBeth JL, Iyer AS, Leggat DJ, Khuder SA, Khaskhely NM, Westerink MJ. Quantitative and Functional Antibody Responses to the 13-Valent Conjugate and/or 23-Valent Purified Polysaccharide Vaccine in Aging HIV-Infected Adults. J AIDS Clin Res. 2016 Mar;7(3):556. doi: 10.4172/2155-6113.1000556. Epub 2016 Mar 14. PMID: 27158552.
Ohtola JA, Khaskhely NM, Saul-Mcbeth JL, Iyer AS, Leggat DJ, Khuder SA, Westerink MAJ. Alterations in serotype-specific B cell responses to the 13-valent pneumococcal conjugate vaccine in aging HIV-infected adults. Vaccine. 2016 Jan 20;34(4):451-457. doi: 10.1016/j.vaccine.2015.12.013. Epub 2015 Dec 18. PMID: 26707220.
Leggat DJ, Iyer AS, Westerink MA. No Benefit to Delaying Pneumococcal Polysaccharide Vaccination in HIV-Positive Adults. J Infect Dis. 2015 Dec 1;212(11):1851-2. doi: 10.1093/infdis/jiv349. Epub 2015 Jun 24. PMID: 26109676.
Iyer AS, Leggat DJ, Ohtola JA, Duggan JM, Georgescu CA, Al Rizaiza AA, Khuder SA, Khaskhely NM, Westerink J. Response to Pneumococcal Polysaccharide Vaccination in HIV-Positive Individuals on Long Term Highly Active Antiretroviral Therapy. J AIDS Clin Res. 2015 Feb;6(2):421. doi: 10.4172/2155-6113.1000421. PMID: 25908996.
Leggat DJ, Iyer AS, Ohtola JA, Kommoori S, Duggan JM, Georgescu CA, Khuder SA, Khaskhely NM, Westerink MJ. Response to Pneumococcal Polysaccharide Vaccination in Newly Diagnosed HIV-Positive Individuals. J AIDS Clin Res. 2015 Feb;6(2):419. doi: 10.4172/2155-6113.1000419. PMID: 25908995.
To view a complete list of Dr. Leggat’s publications, click here: https://www.ncbi.nlm.nih.gov/myncbi/1N59A_7tz8wQN/bibliography/public/